scholarly journals Clinical- pathological features and surgical outcome of renal cell carcinoma: Experience from a zonal referral hospital-northern of Tanzania

2021 ◽  
Vol 12 (2) ◽  
pp. 434-440
Author(s):  
Vitus Kajerero ◽  
Frank Bright ◽  
Orgeness J. Mbwambo ◽  
Alfred K. Mteta ◽  
Patrick Amsi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Advanced Disease ◽  
Abdominal Mass ◽  
Significant Proportion ◽  
Flank Pain ◽  
Pathological Feature ◽  
Female Ratio

Background: Renal cell carcinoma (RCC) is the most common primary malignant tumour of kidney in adults. Recent studies from developed countries have shown that most renal tumour are currently diagnosed incidentally during screening for other disease which leads to better prognosis while few studies done in Africa still shows significant proportion of patients present with classic triad ( >10%) which is a sign of advanced disease. Objectives: This study aimed at determining clinical pathological feature and outcome of RCC in Northern zone of Tanzania. Patients and Methods: This was a hospital based descriptive retrospective cohort study conducted at Kilimanjaro Christian Medical (KCMC) from January 2002 to December 2017. Data were analysed using statistical package for social science (SPSS) version 16. 0 and summarized in tables and figures. Results: Forty three patients (43) underwent radical nephrectomy for RCC during the study period. Male to female ratio was1. 7: 1 with mean age of 53+/- 12 years. Flank pain (84%), abdominal mass (76%) and hematuria (44%) were the most common clinical presentation while classical triad was found in 40%. The most common clinical tumor stage was T3(72. 1%) whilst clear cell carcinoma was the commonest histological pattern. Five years survival length for T1, T2, T3 and T4 were 100%, 62. 5%, 32. 3% and 0% respectively. Conclusion: The most common presenting symptom of RCC in our centre is flank pain, and abdominal mass. Majority of the patients presented with advanced disease with less than five year survival rate. Clear cell type was the predominant histological type.

Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease

Pathology ◽  
2016 ◽  
Vol 48 (6) ◽  
pp. 613-616 ◽  
Author(s):  
Handoo Rhee ◽  
Keng Lim Ng ◽  
Brian Wan-Chi Tse ◽  
Mei-Chun Yeh ◽  
Pamela J. Russell ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Advanced Disease ◽  
Prostate Specific Membrane Antigen ◽  
Cell Renal Cell Carcinoma ◽  
Specific Membrane ◽  
Psma Expression

Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4544-4544
Author(s):  
Youngil Koh ◽  
Ji Yeon Kim ◽  
Ho Yeong Lim ◽  
Jin-Hee Ahn ◽  
Jae-Lyun Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Mtor Inhibitor ◽  
Clear Cell ◽  
Phase Ii Trial ◽  
Collecting Duct ◽  
Female Ratio ◽  
Tki Treatment

4544^ Background: In non-clear cell renal cell carcinoma (ncRCC), the efficacy of VEGF tyrosine kinase inhibitor (TKI) is controversial. In the while, a mTOR inhibitor, temsirolimus showed a promising efficacy in ncRCC patients in ARCC trial. Hence, we investigated the role of everolimus in ncRCC with this phase II trial. Methods: ncRCC patients received everolimus 10 mg once daily until disease progression or unacceptable toxicity. We included patients who had received VEGF TKI previously, while excluded patients who received previous mTOR inhibitor. The primary end point was progression free survival (PFS). Results: A total of 49 patients were enrolled from 5 centers. Their median age was 57 years (range 24-75 years) and male to female ratio was 37:12. Histology of the patients included papillary (n=29), chromophobe (n=8), collecting duct (n=2), sarcomatoid (n=4), and unclassifiable (n=6) RCC. Twenty-three patients had been treated with VEGF-TKI prior to the study enrollment. Among 49 patients, 46 patients underwent radiologic response assessment after everolimus treatment. Partial response was observed in 5 patients (10.2%) and stable disease in 25 patients (51.0%). Diseases of 16 patients (32.7%) progressed despite of everolimus administration. Histology of 5 patients who showed objective response to everolimus included chromophobe carcinoma (n=2), papillary carcinoma (n=2) and unclassifiable carcinoma (n=1). During the study period, 34 patients experienced PFS events and median PFS was 5.2 months. Patients with chromophobe histology showed longer PFS than patients with the other histologies (median PFS 18.8 months vs. 3.5 months, p=0.027). Estimated median PFS were not significantly different between patients VEGF-TKI treatment and patients without previous VEGF-TKI treatment (median PFS 7.1 vs. 3.7 months, p=0.110). Toxicity profiles were commensurable with previous reports. Conclusions: Everolimus shows considerable efficacy in ncRCC. Patients with chromophobe histology might earn benefit from everolimus treatment especially. Previous treatment with VEGF-TKI seems not to significantly influence outcome of everolimus therapy in these patients. (ClinicalTrials.gov number, NCT00830895)

Genito-urinary cancer

2011 ◽  
Author(s):  
Thankamma Ajithkumar ◽  
Ann Barrett ◽  
Helen Hatcher ◽  
Natalie Cook
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Solid Tumour ◽  
Clear Cell ◽  
Urological Cancer ◽  
Cell Renal Cell Carcinoma ◽  
Female Ratio ◽  
The Uk ◽  
Male To Female

Renal cell carcinoma (RCC) accounts for approximately 2% of cancer diagnosis worldwide. It has the highest mortality of any urological cancer. Clear-cell renal cell carcinoma (CC-RCC) is the commonest RCC. CC-RCC has the highest prevalence in Eastern Europe and is the fifth commonest solid tumour in the UK. Incidence of primary CC-RCC rises after the age of 40 years old and there is a 2:1 male to female ratio....

638: Macroscopic Tumor Necrosis is a Prognostic Indicator for Non-Metastatic Clear Cell Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 214-214
Author(s):  
Sung Kyu Hong ◽  
Byung Kyu Han ◽  
In Ho Chang ◽  
June Hyun Han ◽  
Ji Hyung Yu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Necrosis ◽  
Clear Cell ◽  
Prognostic Indicator ◽  
Cell Renal Cell Carcinoma ◽  
Macroscopic Tumor

Rare localization of renal cell carcinoma metastases in the paranasal sinuses and breast: a case report

2019 ◽  
Vol 22 (6) ◽  
pp. 13-22
Author(s):  
E. V. Kryaneva ◽  
N. A. Rubtsova ◽  
A. V. Levshakova ◽  
A. I. Khalimon ◽  
A. V. Leontyev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paranasal Sinuses ◽  
Renal Cell ◽  
Clinical Case ◽  
Clear Cell ◽  
Malignant Tumors ◽  
Metastatic Potential ◽  
Cell Renal Cell Carcinoma ◽  
Metastatic Lesions

This article presents a clinical case demonsratinga high metastatic potential of clear cell renal cell carcinoma combined with atypical metastases to breast and paranasal sinuses. The prevalence of metastatic lesions to the breast and paranasal sinuses in various malignant tumors depending on their morphological forms is analyzed. The authors present an analysis of data published for the last 30 years. The optimal diagnostic algorithms to detect the progression of renal cell carcinoma and to evaluate the effectiveness of the treatment are considered.

Sign in / Sign up

Export Citation Format

Share Document